Navigation Links
Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
Date:3/13/2009

NEW YORK, March 13 /PRNewswire/ -- Jina Ventures is pleased to announce the acquisition of clinical pharmacology and research company, Swiss Pharma Contract (SPC) by leading contract research organization, Covance Inc (NYSE: CVD). Jina Ventures was the exclusive financial advisor to SPC in the transaction, which provides Covance with the facilities and services of Basel, Switzerland area-based SPC.

"We are thrilled to have been an integral part of a deal that we believe adds real value to a well-established global player," said Ron Shah, Managing Partner, Jina Ventures. "There were bids for SPC from several global clinical research organizations, but Covance presented the most compelling opportunity for strategic long-term growth for SPC."

SPC was seed-funded by Novartis Venture Fund in 1998, and provides Phase I clinical trials to leading pharmaceutical clients and biotechnology companies in Europe, the United States and Asia. SPC's leadership includes Dr. Rolf Pokorny and Dr. Michael Seiberling, two industry veterans in the field of Phase I clinical trials.

Jina Ventures invigorated the M&A process by using a customized global auction, which resulted in interest from 14 leading companies, based in Europe, Asia and the U.S. As worldwide M&A volume has declined over the last 12 months, auctions continue to be an effective way to utilize global competitiveness to drive deal value and strategic fit.

On the heels of this transaction, Jina Ventures is poised for major growth in 2009, targeting the close of a second life sciences M&A transaction by mid-year and the launch of its second fund of US$200 million later this year. Jina's second fund is a cross border private equity fund designed to leverage global competitiveness for its portfolio companies in the US and India.

About Jina Ventures:

Founded in 2003, Jina Ventures is a New York-based private equity and M&A advisory firm. Over the past 6 years, Jina Ventures has grown into a full service private equity practice, with both principal investing and cross-border mergers and acquisitions. In addition to New York City, Jina Ventures also has offices in Mumbai, Tokyo, Bangkok and Singapore. More information can be found at www.jinaventures.com.


'/>"/>
SOURCE Jina Ventures
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone ... story-driven, knowledge-based and mobile-friendly. Visit the new site: ... ... ... "The goal was to reimagine the ...
(Date:2/5/2016)... 5, 2016  In the pharmaceutical industry the medical ... of launch activities including the identification and engagement of ... is especially high in the oncology therapeutic area where ... and the Role of Medical Affairs in Oncology Launch ... oncology therapies find better ways to utilize medical affairs ...
(Date:2/4/2016)... New FDA action date of July 22, ... July 22, 2016   --> - ... - Lifitegrast has the potential to be the only ... signs and symptoms of dry eye disease in adults --> ... approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... commercializing its flagship CytoSorb® blood filter to treat ... around the world, announced that CEO Dr. ... the Source Capital Group,s 2016 Disruptive Growth & ... the company.  Conference Presentation Details: ...
Breaking Biology Technology:
(Date:1/11/2016)... 11, 2016  higi, the leading retail and ... locations, web and mobile, today announced it has ... existing investors. --> ... further innovate higi,s health platform – its network ... – including expanding services and programs to retail ...
(Date:1/7/2016)... 7, 2016 This BCC Research report studies ... technologies and devices, identifying newer markets and exploring the ... of biometric devices. Includes forecast from 2015 to 2020. ... markets and explore the expansion of the present application ... type of biometric technology, determine its current market size, ...
(Date:1/6/2016)... PLEASANTON, Calif. , Jan. 6, 2016  Varam ... SayPay as their trusted partner to deliver advanced authentication ... other financial services to the poor. A loan of ... in their lives, giving them the ability to purchase ... machine to make clothing, or stock for a local ...
Breaking Biology News(10 mins):